Table 1 Neuropeptide Y family receptors with preferred ligands, receptor distribution and function in food intake and fat deposition
From: Hypothalamus-adipose tissue crosstalk: neuropeptide Y and the regulation of energy metabolism
| Â | Y1 | Y2 | Y4 | Y5 | |
|---|---|---|---|---|---|
Preferred ligand | NPY | NPY | PP | NPY | |
Requires a complete N terminus | NPY3-36 | NPY | NPY2-36 | ||
Requires intact C-terminal fragments | NPY3-36 | ||||
Pre vs. post junctional receptor | Post-junctional | Pre-junctional | Post-junctional | Post-junctional | |
Distri-bution | Brain (besides hypotha-lamus) | Cortex, brainstem, hippocampus, thalamus, amygdala | Cortex, brainstem, hippocampus, amygdala, striatum, nucleus accumbens | Subnucleus gelatinosus of NTS, dorsal motor nucleus of the vagus | Cortex, hippocampus, amygdala |
Hypoth-alamus | ARC, VMN, PVN, DMN, LH Supraoptic nucleus | ARC, PVN, LH, medial preoptical area, anterior hypothalamic nucleus | ARC, PVN | PVN, ARC, VMN, DMN, LH | |
Perip-heral | Thyroid, parathyroid glands, heart, spleen and digestive system, adipose tissue | Adipose tissue | Skeletal muscle, small intestine, pancreas, prostate, uterus, lung, colon | Adipose tissue | |
Types of manipulation/Effects on food intake and body weight | Y1 antagonist central injection/Reduced food intake[15, 16]; Y1 agonist central injection/Increase food intake[17]; Y1KO/Developed obesity, increased body fat, slight reduction in food intake[18, 19] | Y2 agonist IP injection/ inhibit food intake[20]; Hypothalamus-specific Y2 KO/Increased food intake and decreased body weight; Germ-line Y2 KO/Reduced body weight and adiposity, reduced food intake in males and increased food intake in females[21] | Y4 KO/Decreased body weight, less WAT, decreased 24-h food intake in male mice[22] | Central administration of Y5 antisense oligodeoxynucleotides/Reduced body weight and a decrease in food intake[23, 24]; Y5 KO/ Mild late-onset obesity, increased body weight, food intake and adiposity[25] | |